Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1390029
European Journal of Endocrinology, Vol 139, Issue 1, 29-35
Copyright © 1998 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bollerslev, J
Right arrow Articles by Djoseland, O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bollerslev, J
Right arrow Articles by Djoseland, O
Articles

Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine

J Bollerslev, T Ueland, E Grodum, E Haug, K Brixen, and O Djoseland

Department of Medical Endocrinology, National University Hospital, Oslo, Norway.

Biochemical markers of bone remodelling were used to evaluate bone turnover in two types of autosomal dominant osteopetrosis (ADO) at baseline and during stimulation with triiodothyronine (T3). Eight patients with Type I (aged 23-61 years, mean 40.4 years) and nine patients with Type II ADO (aged 20-49 years, mean 32.8 years) were compared with 10 normal controls (aged 22-54 years, mean 35.4 years). The participants were treated with 100 microg T3 daily for 7 days and followed for a total of 16 weeks. Serum concentrations of T3 increased and corresponding suppression of TSH was observed in all participants. Both formative and resorptive bone markers were normal at baseline. After stimulation with T3, a significant increase was seen in all groups for the formative markers used. Secondary increments were observed at the end of the observation period for all groups, indicating activation of bone remodelling. A variety of resorptive markers was assessed, but no differences between patients and controls were seen. After stimulation, highly significant responses were found in all parameters in all groups, in accordance with stimulation of existing resorptive cells. However, no secondary increments were seen at the end of the observation period. A more pronounced response was found in crosslinks-related assays. The study demonstrates that it is possible to stimulate bone resorptive and formative cells with thyroid hormones in both types of ADO. Moreover, it indicates that the remodelling process is activated by a short course of T3 treatment.


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
K. Henriksen, J. Gram, P. Hoegh-Andersen, R. Jemtland, T. Ueland, M. H. Dziegiel, S. Schaller, J. Bollerslev, and M. A. Karsdal
Osteoclasts from Patients with Autosomal Dominant Osteopetrosis Type I Caused by a T253I Mutation in Low-Density Lipoprotein Receptor-Related Protein 5 Are Normal in Vitro, but Have Decreased Resorption Capacity in Vivo
Am. J. Pathol., November 1, 2005; 167(5): 1341 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
T. J. Martin
New Aspects of Wnt Signalling Revealed by Mouse and Human Genetics
IBMS BoneKEy, October 1, 2005; 2(10): 7 - 11.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. L. Alatalo, K. K. Ivaska, S. G. Waguespack, M. J. Econs, H. K. Vaananen, and J. M. Halleen
Osteoclast-Derived Serum Tartrate-Resistant Acid Phosphatase 5b in Albers-Schonberg Disease (Type II Autosomal Dominant Osteopetrosis)
Clin. Chem., May 1, 2004; 50(5): 883 - 890.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 European Society of Endocrinology.